This study provides model-based economic evidence for optimizing treatment pathways in HER2-low metastatic breast cancer, suggesting that the use of ADCs may not be cost-effective under current pricing. It offers direct guidance for [[tumor drug development]] and the design of [[personalized treatment strategies]].
Literature Overview
The article "The Cost and Cost-Effectiveness of Treating HER2-low Metastatic Breast Cancer," published in the Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, systematically examines the economic rationale of treatment sequences involving antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in patients with HER2-low metastatic breast cancer. Using a decision-analytic model, the study evaluates the long-term costs and health outcomes of different treatment strategies, providing key reference data for healthcare payers and clinical guideline development. The research context reflects the rapidly evolving landscape of breast cancer therapy, where escalating treatment costs pose growing challenges. In particular, HER2-low tumors—which constitute 56–65% of the traditionally defined 'HER2-negative' population—have seen significant efficacy improvements with the introduction of novel ADCs, but at a high financial cost. Although T-DXd and SG are FDA-approved for this population, a lack of head-to-head comparisons or prospective data on sequential use leaves the optimal treatment sequence unclear. Furthermore, current value assessment frameworks lag in integrating high-cost, high-efficacy drugs, creating an urgent need for real-world parameter-based economic models to inform decision-making. This study fills a critical evidence gap between treatment pathway optimization and cost-effectiveness.Background Knowledge
1. The key challenge in [[metastatic breast cancer]] addressed by this study is that while novel [[ADCs]] significantly extend progression-free and overall survival, their extremely high prices place substantial strain on healthcare systems—particularly in advanced patients requiring multiple lines of therapy—making the balance between clinical benefit and economic sustainability a core challenge. 2. The current research bottleneck in [[HER2-low]] lies in the fact that although both T-DXd and SG demonstrate superior efficacy over chemotherapy, clinical evidence on their sequential use remains limited, and cost-effectiveness analyses are lacking, leading to risks of overuse or suboptimal sequencing in clinical practice. 3. The study’s entry point involves integrating survival data from pivotal trials such as DESTINY-Breast04 with real-world cost parameters to build a Markov model simulating long-term patient outcomes, thereby quantifying the incremental cost-effectiveness ratio (ICER) of different treatment sequences and providing quantitative support for insurance negotiations and clinical pathway design. The research specifically examines the pricing elasticity of [[T-DXd]], assessing at what price point it might meet conventional cost-effectiveness thresholds, while also exploring the economic implications of back-to-back ADC use. The model incorporates key variables such as [[health-related quality of life]], [[adverse events]] (e.g., [[ILD]]), and the likelihood of subsequent therapies, enhancing the generalizability of the findings to real-world settings.
Research Methods and Experiments
The authors employed a population-based decision-analytic Markov model to simulate four treatment strategies for a 57-year-old female patient with HER2-low metastatic breast cancer in the third-line setting: chemotherapy → chemotherapy, T-DXd → chemotherapy, chemotherapy → T-DXd, and T-DXd → SG. The model was calibrated using progression-free survival (PFS) and overall survival (OS) data from the DESTINY-Breast04 trial to ensure alignment between simulated outcomes and real-world efficacy. Transition probabilities, mortality rates, adverse event (e.g., [[ILD]]) incidence, and treatment discontinuation rates were derived from published clinical trials. Cost parameters were synthesized from the Federal Supply Schedule (FSL), Medicare reimbursement rates, and bundled costs for adverse events reported in the literature, with all costs expressed in 2020 USD and discounted at an annual rate of 3%. Utility values (QALYs) were based on health state utility weights from the literature, ranging from 0.4 to 0.8, reflecting the quality of life in patients with [[metastatic breast cancer]]. A probabilistic sensitivity analysis using 1,000 Monte Carlo simulations was conducted to assess uncertainty in input parameters, and cost-effectiveness acceptability curves (CEAC) were used to illustrate the optimal strategy across different willingness-to-pay thresholds.Key Conclusions and Perspectives
Research Significance and Prospects
This study offers important implications for [[drug development]]: when developing new [[ADCs]] or targeted therapies, early economic modeling should be conducted in parallel to assess their sustainability within real-world healthcare systems. Pharmaceutical companies should consider differential pricing or outcomes-based payment models to enhance market access. Additionally, the study underscores the need for strict adherence to evidence-based pathways in [[clinical monitoring]], avoiding the sequential use of high-cost drugs without clear indications, especially in the absence of survival benefit. For the field of [[disease modeling]], this research demonstrates how to integrate heterogeneous data sources (clinical trials, cost data, utility values) into a robust decision model, offering a methodological template for evaluating treatment pathways in other cancers or chronic diseases. Future studies could refine the model by incorporating biomarker-guided treatment selection, subgroup analyses by HR status, and longer follow-up data to improve predictive accuracy.
Conclusion
This study, using a rigorous decision-analytic model, reveals that despite the clear clinical benefits of [[T-DXd]] in HER2-low metastatic breast cancer, its use does not meet traditional cost-effectiveness standards under the current pricing structure. In particular, the sequential use of two [[ADCs]] imposes a heavy economic burden with minimal incremental health gains, representing low-value care. The findings provide strong negotiation leverage for payers such as U.S. Medicare, calling for a price reevaluation of T-DXd. From a translational perspective—from bench to bedside—the study emphasizes that precision oncology requires not only precise biomarker matching but also precise economic value assessment. In the future, cost-effectiveness analyses should be integrated into clinical guidelines, similar to NCCN evidence blocks, to enable truly personalized and sustainable cancer care. For [[metastatic breast cancer]] care systems, this study provides foundational evidence for optimizing treatment pathways, controlling healthcare expenditures, and improving resource allocation efficiency, driving a shift from 'more treatment' to 'better value.'
